Publicaciones en las que colabora con MARÍA VICTORIA CALVO HERNÁNDEZ (25)

2011

  1. Modification of the EMIT immunoassay for the measurement of unbound mycophenolic acid in plasma

    Clinical Biochemistry, Vol. 44, Núm. 2-3, pp. 260-263

2010

  1. Clinical repercussions of analytical interferences due to aldosterone antagonists in digoxin immunoassays: An assessment

    Therapeutic Drug Monitoring, Vol. 32, Núm. 2, pp. 169-176

2009

  1. Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients

    Journal of Pharmacy and Pharmacology, Vol. 61, Núm. 6, pp. 759-766

2007

  1. Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients

    Intensive Care Medicine, Vol. 33, Núm. 2, pp. 279-285

2004

  1. Pharmacokinetic basis for the use of extended interval dosage regimens of gentamicin in neonates

    Journal of Antimicrobial Chemotherapy, Vol. 54, Núm. 1, pp. 193-198

1999

  1. Population pharmacokinetics of amikacin in patients with haematological malignancies

    Journal of Antimicrobial Chemotherapy, Vol. 44, Núm. 2, pp. 235-242

1998

  1. Multicriteria decision analysis for determining drug therapy for intermittent claudication

    Methods and Findings in Experimental and Clinical Pharmacology, Vol. 20, Núm. 5, pp. 425-431

1997

  1. Minimizing digoxin-like immunoreactivity with TDx digoxin in dialysis patients [1]

    Therapeutic Drug Monitoring

1996

  1. Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies

    Clinical Pharmacology and Therapeutics, Vol. 60, Núm. 3, pp. 332-340

  2. Influence of pharmacokinetic model on vancomycin peak concentration targets

    Therapeutic Drug Monitoring, Vol. 18, Núm. 2, pp. 145-148

  3. Pharmacokinetics of amikacin in intensive care unit patients

    Journal of Clinical Pharmacy and Therapeutics, Vol. 21, Núm. 6, pp. 417-421

1994

  1. ANALISIS DE DECISION PARA EVALUAR LA RELACION COSTE-EFECTIVIDAD DE LOS MEDIOS DE CONTRASTE DE BAJA OSMOLARIDAD EN UROGRAFIAS INTRAVENOSAS

    Farmacia Clinica, Vol. 11, Núm. 1, pp. 9-20

1992

  1. Decision analysis to assess cost-effectiveness of low-osmolality contrast medium for intravenous urography

    American Journal of Hospital Pharmacy, Vol. 49, Núm. 3, pp. 577-584

  2. EL METAANALISIS COMO TECNICA CUANTITATIVA DE LAS REVISIONES DE LA LITERATURA

    Farmacia Hospitalaria, Vol. 16, Núm. 4, pp. 225-234

1991

  1. H2-receptor antagonists and acute intermittent porphyria [3]

    American Journal of Hospital Pharmacy

1990

  1. ANALISIS DE DECISION EN LA TERAPEUTICA ANTIBIOTICA

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 8, Núm. 4, pp. 199-207

  2. Decision analysis applied to selection of histamine H2-receptor antagonists for the formulary

    American Journal of Hospital Pharmacy, Vol. 47, Núm. 9, pp. 2002-2006

1988

  1. Farmacia hospilataria XXXII

    Sociedad Española de Farmacia Hospitalaria

1987

  1. Bioavailability of rectally administered naproxen

    International Journal of Pharmaceutics, Vol. 38, Núm. 1-3, pp. 117-122

1985

  1. Pharmacokinetics and initial distribution of a new neuroleptic agent picobenzide (M-14012-4)

    International Journal of Clinical Pharmacology Therapy and Toxicology, Vol. 23, Núm. 5, pp. 233-237